BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37781363)

  • 21. Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.
    Xiong Y; Wang J; Zhu H; Liu L; Jiang Y
    Oncol Rep; 2018 Mar; 39(3):967-976. PubMed ID: 29328404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.
    Tsoumas D; Nikou S; Giannopoulou E; Champeris Tsaniras S; Sirinian C; Maroulis I; Taraviras S; Zolota V; Kalofonos HP; Bravou V
    Cancer Genomics Proteomics; 2018; 15(2):127-141. PubMed ID: 29496692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.
    Yuan W; Ji J; Shu Y; Chen J; Liu S; Wu L; Zhou Z; Liu Z; Tang Q; Zhang X; Shu X
    J Mol Med (Berl); 2019 Jan; 97(1):89-102. PubMed ID: 30460377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
    Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
    Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells.
    Skarkova V; Kralova V; Krbal L; Matouskova P; Soukup J; Rudolf E
    Exp Cell Res; 2018 Aug; 369(2):295-303. PubMed ID: 29842879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Interleukins in Inflammation-Mediated Tumor Immune Microenvironment Modulation in Colorectal Cancer Pathogenesis.
    Jain SM; Deka D; Das A; Paul S; Pathak S; Banerjee A
    Dig Dis Sci; 2023 Aug; 68(8):3220-3236. PubMed ID: 37277647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An extracellular matrix (ECM) model at high malignant colorectal tumor increases chondroitin sulfate chains to promote epithelial-mesenchymal transition and chemoresistance acquisition.
    Hoshiba T
    Exp Cell Res; 2018 Sep; 370(2):571-578. PubMed ID: 30016638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
    Zhang L; Wu H; Zhang Y; Xiao X; Chu F; Zhang L
    Bioengineered; 2022 Jan; 13(1):950-962. PubMed ID: 34969360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
    Erin N; Grahovac J; Brozovic A; Efferth T
    Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
    Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
    J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.
    Hu JL; Wang W; Lan XL; Zeng ZC; Liang YS; Yan YR; Song FY; Wang FF; Zhu XH; Liao WJ; Liao WT; Ding YQ; Liang L
    Mol Cancer; 2019 May; 18(1):91. PubMed ID: 31064356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.
    Liu H; Ren G; Wang T; Chen Y; Gong C; Bai Y; Wang B; Qi H; Shen J; Zhu L; Qian C; Lai M; Shao J
    Carcinogenesis; 2015 Apr; 36(4):459-68. PubMed ID: 25750173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
    Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
    Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased chemoresistance via Snail-Raf kinase inhibitor protein signaling in colorectal cancer in response to a nicotine derivative.
    Lee TY; Liu CL; Chang YC; Nieh S; Lin YS; Jao SW; Chen SF; Liu TY
    Oncotarget; 2016 Apr; 7(17):23512-20. PubMed ID: 26992205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma.
    Chen L; Jin XH; Luo J; Duan JL; Cai MY; Chen JW; Feng ZH; Guo AM; Wang FW; Xie D
    Oncogene; 2021 Oct; 40(40):5925-5937. PubMed ID: 34363021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6.
    Yin Y; Yao S; Hu Y; Feng Y; Li M; Bian Z; Zhang J; Qin Y; Qi X; Zhou L; Fei B; Zou J; Hua D; Huang Z
    Clin Cancer Res; 2017 Dec; 23(23):7375-7387. PubMed ID: 28928161
    [No Abstract]   [Full Text] [Related]  

  • 39. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.
    Li H; Rokavec M; Jiang L; Horst D; Hermeking H
    Gastroenterology; 2017 Aug; 153(2):505-520. PubMed ID: 28435028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DYRK2 downregulation in colorectal cancer leads to epithelial-mesenchymal transition induction and chemoresistance.
    Wu C; Sun G; Wang F; Chen J; Zhan F; Lian X; Wang J; Weng F; Li B; Tang W; Quan J; Xiang D
    Sci Rep; 2022 Dec; 12(1):22496. PubMed ID: 36577753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.